0001209191-23-017636.txt : 20230309 0001209191-23-017636.hdr.sgml : 20230309 20230309182159 ACCESSION NUMBER: 0001209191-23-017636 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230307 FILED AS OF DATE: 20230309 DATE AS OF CHANGE: 20230309 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: PIMSTONE SIMON N. CENTRAL INDEX KEY: 0001620084 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 23721083 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G4W8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-03-07 0 0001582313 Xenon Pharmaceuticals Inc. XENE 0001620084 PIMSTONE SIMON N. 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 BRITISH COLUMBIA, CANADA 1 0 0 0 Common Shares 2023-03-07 4 M 0 41152 2.68 A 47152 D Common Shares 2023-03-07 4 F 0 2160 37.13 D 44992 D Common Shares 2023-03-07 4 S 0 10990 37.01 D 34002 D Common Shares 2023-03-07 4 M 0 30864 2.59 A 64866 D Common Shares 2023-03-07 4 F 0 1618 37.13 D 63248 D Common Shares 2023-03-07 4 S 0 8242 36.94 D 55006 D Stock Option (Right to Buy) 2.68 2023-03-07 4 M 0 41152 0.00 D 2023-03-10 Common Shares 41152 0 D Stock Option (Right to Buy) 2.59 2023-03-07 4 M 0 30864 0.00 D 2023-03-09 Common Shares 30864 0 D The exercise price was converted to U.S. dollars from $2.67 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Represents the closing price of the Company's common shares on March 6, 2023 for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.93 to $37.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $36.89 to $37.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares subject to the options are fully vested and exercisable. Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period. /s/ Cassandra Robinson, Power of Attorney 2023-03-09